Novonesis (Novozymes) B
Company Profile
Business description
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
Contact
Krogshoejvej 36
Bagsvaerd2880
DNKT: +45 44460000
Sector
Basic Materials
Stock type
Cyclical
Industry
Specialty Chemicals
Fiscal Year End
31 December 2025
Employees
10,582
Stocks News & Analysis
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
stocks
Why I dislike dividend stocks
stocks
Chart of the Week: Ramsay Health Care margins to rebound
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,293.20 | 45.10 | -0.48% |
| CAC 40 | 8,212.73 | 24.14 | 0.29% |
| DAX 40 | 23,979.92 | 292.27 | -1.20% |
| Dow JONES (US) | 46,084.27 | 132.03 | 0.29% |
| FTSE 100 | 9,377.18 | 58.91 | -0.62% |
| HKSE | 25,247.10 | 641.41 | -2.48% |
| NASDAQ | 22,612.54 | 50.01 | 0.22% |
| Nikkei 225 | 47,582.15 | 695.59 | -1.44% |
| NZX 50 Index | 13,289.21 | 99.89 | -0.75% |
| S&P 500 | 6,643.90 | 14.83 | 0.22% |
| S&P/ASX 200 | 8,995.30 | 34.70 | -0.38% |
| SSE Composite Index | 3,839.76 | 76.47 | -1.95% |